NCT03712358View on ClinicalTrials.gov

PVSRIPO for Patients With Unresectable Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions
Melanoma
Interventions
BIOLOGICAL

PVSRIPO

Intralesional injection of PVSRIPO.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Istari Oncology, Inc.

INDUSTRY

NCT03712358 - PVSRIPO for Patients With Unresectable Melanoma | Biotech Hunter | Biotech Hunter